Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke (Q36269180)

13 August 2017

1 reference

title

Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke (English)

1 reference

13 August 2017

0 references

Muriel J Caslake

1

1 reference

13 August 2017

Chris J Packard

series ordinal

2

1 reference

13 August 2017

publication date

1 October 2005

1 reference

Nature Clinical Practice Cardiovascular Medicine

13 August 2017

published in

1 reference

13 August 2017

volume

2

1 reference

13 August 2017

issue

10

1 reference

13 August 2017

page(s)

529-535

1 reference

Atherosclerosis — An Inflammatory Disease

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Platelet-activating factor acetylhydrolases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Platelet-activating factor acetylhydrolase: is it good or bad for you?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Subendothelial retention of atherogenic lipoproteins in early atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Lp-PLA2: an emerging biomarker of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Cardiovascular disease risk profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

Phospholipase A(2) in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Sol Sherry lecture in thrombosis: molecular events in acute inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Human platelets release a paf-acether: acetylhydrolase similar to that in plasma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Lipoprotein-Associated Phospholipase A 2 , Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0321

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0321

1 reference

13 August 2017

1 reference